US OptionsDetailed Quotes

HOOK241018C500

Watchlist

0.15
0.000.00%

15min DelayClose Jul 8 15:28 ET

0.00High0.00Low

HOOKIPA Pharma Stock Discussion

Trytosaveabit

Sep 24 06:48

Watching! Look at date/time!

$HOOKIPA Pharma (HOOK.US)$ HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset
16 MINUTES AGO, 7:30 AM EDT
VIA GLOBENEWSWIRE
NEW YORK and VIENNA, Sept. 24, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK) ("HOOKIPA" or the "Company"), a clinical-stage biopharmaceutical company developing next generation immunotherapeutics for the treatment of cancer and serious infectious diseases, today announced that the Company will present preclinical data related...

CUP9150

Jul 10 15:28

$HOOKIPA Pharma (HOOK.US)$

Jaguar8

Jul 8 06:03

NEWS

$HOOKIPA Pharma (HOOK.US)$
HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split - July 10,2024

Trytosaveabit

Jul 1 15:36

Update

$HOOKIPA Pharma (HOOK.US)$ HOOKIPA Pharma Inc - HOOKIPA Achieves a $5 Mln Non-Dilutive Milestone Payment Under Its Collaboration and License Agreement With Gilead

FattyChick

Jul 1 15:32

$HOOKIPA Pharma (HOOK.US)$ Good news after-market 👀

LeoforDharma

Jun 20 05:40

Update Insider Buying

$HOOKIPA Pharma (HOOK.US)$
Ladies and gentleman, On the 17 June 2024, 5 directors and 1 chairperson have collectively bought over 340K of shares at around 0.71 $.
Just wanted to share .... 😊

LeoforDharma

Jun 18 10:18

Shorties move away plz

$HOOKIPA Pharma (HOOK.US)$
Up down up down, these shorties will never let us live in peace 🤬🤬🤬

LeoforDharma

Jun 14 12:36

Damn

$HOOKIPA Pharma (HOOK.US)$ @Trytosaveabit
Why is this stock doing so bad? I mean for a clinical stage companythey are even profitable at this quarter means their product must be at least good right ?

Trytosaveabit

Jun 4 12:05

News

$HOOKIPA Pharma (HOOK.US)$ HOOKIPA Pharma Announces Phase 2 Results For HB-200 Combined With Pembrolizumab In HPV16+ Head And Neck Cancer
Benzinga· 1 min ago
Encouraging clinical activity with observed deepening of responses in 35 evaluable first line head and neck patients treated with HB-200 plus pembrolizumab
In a subset of 17 evaluable patients with PD-L1 combined positive score (CPS) of 20 or higher, the Company's selected registrational pivotal trial population, data showed confirmed OR...

Jaguar8

Jun 4 12:01

NEWS

$HOOKIPA Pharma (HOOK.US)$
HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting
HOOKIPA Pharma announced updated Phase 2 clinical data for HB-200 combined with pembrolizumab in treating recurrent/metastatic HPV16+ head and neck cancer at the ASCO 2024 Annual Meeting. Out of 35 evaluable patients, results showed a 37% confirmed objective response rate (ORR), 11% complete response (CR) rate, and 69% disease control rate (DCR). N...

No comment yet